|
Oct.13(Wed.) 10 : 00 ~ 11 : 30 |
F203-206 |
| 【K-1】 Keynote Lecture |
|---|
|
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)
Keynote Lecture
|
|
Challenges & Prospects of Japan's STI Policy Toward Realizing Society 5.0 Koichi AKAISHI 【Remote Presentation】 George Hara Chairman of the Board, Alliance Forum Foundation / Group Chairman and CEO, DEFTA Partners
Japanese
"Current status and issues of infection control in Japan" - COVID-19 as an example - Isao Teshirogi, Ph.D. President and CEO
Japanese
|
| 【S-21】 Noster Inc. |
|---|
|
Pre-Registration required Simultaneous interpretation Online Seminar
Future technologies to deepen gut microbiome researchWith the progress of genome science, the study of gut microorganisms has shifted from isolation and identification to a bird's eye view of the microbiota and microbiome. In the future, the knowledge of intestinal microbiota and diseases and health will be further deepened through genomic analysis at the single-cell level, metabolomics analysis of a vast number of molecules, and information science such as cohort studies to reveal the relationship between health conditions and diseases and intestinal microbiota. In this seminar, we would like to introduce examples of these research together with research that develop functional molecules and functional microorganisms as concrete tools with an example of probiotics, HYA, development and discuss future trends in gut microbial research. |
|
Gut microbiome research with omics and information sciences and what links them -progress in postbiotics, HYA, development- Prof. Ogawa Jun Professor
Japanese
Advanced lipidomics technology and its application to elucidate the complex lipid diversity of the gut ecosystem Prof. Arita Makoto Professor
Japanese
Noster company’s information Dr. Yonejima Yasunori Research Manager
Japanese
|
| 【S-22】 Bayer Yakuhin, Ltd. |
|---|
|
Pre-Registration required Online Seminar
Research and Development Strategy and Open Innovation at Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Pharmaceuticals Division at Bayer is globally conducting research and development activities with the goal of delivering innovative prescription drugs to patients, focusing on the fields of cardiovascular and nephrology, oncology, ophthalmology, gynecology, hematology, and diagnostic imaging. |
|
Bayer Pharmaceuticals’ Approach to Innovation Dr. Christian Rommel Head of Research & Development and Member of Executive Committee of Bayer AG Pharmaceuticals 
|
|
Oct.13(Wed.) 11 : 30 ~ 12 : 30 |
F201-202 |
| 【L-1】 TAKARA BIO INC. |
|---|
|
Pre-Registration required
The latest trends in development of the next generation CAR-T
Coordinator Dr. Mineno Junichi Senior Corporate Officer & COO |
|
Dr. Kagoya Yuki Chief
Japanese
Mr. Masanobu Kimura Takara Bio Inc.
Japanese
|
|
Oct.13(Wed.) 13 : 00 ~ 14 : 00 |
F201-202 |
| 【S-1】 Takeda Pharmaceutical Company Limited |
|---|
|
Pre-Registration required
The Future of Cancer Treatment and Healthcare Shaped by Technology and Data Science
This seminar will highlight the commitment of Takeda's Japan Oncology business to improve treatment outcomes for cancer patients through partnerships. Coordinator Mr. Takafumi Horii Senior Vice President, Head of Japan Oncology Business Unit 
|
|
Creating the future of cancer treatments based on data science Dr. Katsuya Tsuchihara Chief, Division of Translational Informatics
Japanese
Developing a new city based on problem-solving to enhance well-being Mr. Kazunori Yamashita Managing Officer, General Manager
Japanese
Contributing to the improvement of cancer patient treatment outcomes Dr. Jumpei Soeda Head
Japanese
Panel Discussion Ms. Yukiko Sakakibara Head
Japanese
|
|
Oct.13(Wed.) 13 : 00 ~ 14 : 00 |
F203-204 |
| 【S-2】 BASF Japan Ltd. |
|---|
|
Pre-Registration required
BASF Japan Ltd. Sponsored SeminarWe will hold a collaboration seminar with Professor Satoshi Yamazaki of University of Tsukuba. BASF will present new solutions for BASF pharmaceutical excipients for cell culture, and Professor Satoshi Yamazaki will present about "Development of expansion technology for haematopoietic-stem-cell and its clinical application". In this presentation, Professor Satoshi Yamazaki will share innovative results on ex vivo haematopoietic-stem-cell expansion using BASF polymer. Please join our seminar and feel the fusion of chemistry and biology! |
|
Introduction of new solutions for BASF pharmaceutical excipients for cell culture Mr. Tsubasa Sano Technical Service
Japanese
Development of expansion technology for hematopoietic stem cells and its clinical application Prof. Satoshi Yamazaki Professor
Japanese
|
|
Oct.13(Wed.) 14 : 30 ~ 15 : 30 |
F203-204 |
| 【S-9】 INFOCOM CORPORATION / H1 Insights,Inc. |
|---|
|
Pre-Registration required
Supporting digital transformation in the healthcare industry ~ Introduction of world's largest KOL database ~
|
|
Supporting the Digital Transformation of the Healthcare Industry - Action of Infocom and H1 Insights Hideakii Kaji Infocom Corporation
Japanese
How to Optimize KOL Engagement in the Digitalized World Ms. Yuki Wick Customer Success Manager
Japanese
Infocom Solutions and Case Study with H1 Data. Eiji Yamabe Infocom Corporation
Japanese
|
|
Oct.13(Wed.) 16 : 00 ~ 17 : 00 |
F205-206 |
| 【S-6】 MEDICAL & BIOLOGICAL LABORATORIES CO., LTD. |
|---|
|
Pre-Registration required
Drug Discovery Services of JSR Life Sciences Group
JSR Life Sciences brings together the deep biochemical knowledge and understanding of human disease, expertise in drug discovery and development, and access to capital into a single, integrated framework that creates value for our customers. We will introduce our recent challenges with new products and services of JLS group companies, MBL and Crown Bioscience. |
|
Strategies for Antibody-Drug Discovery Support Mr. Jun-ichi Akatsuka MEDICAL & BIOLOGICAL LABORATORIES CO., LTD.
Japanese
New Innovation of Animal Modeling for Oncology Drug Discovery Dr. Jessie Wang Senior Director 
|
|
Oct.13(Wed.) 16 : 00 ~ 17 : 00 |
F203-204 |
| 【S-18】 Chugai Pharmaceutical Co., Ltd. |
|---|
|
Pre-Registration required Simultaneous interpretation
Chugai Pharmaceutical Co., Ltd.
|
|
Open innovation in Chugai and comprehensive collaboration between IFReC Mr. Kunihiro Hattori Associate Vice President, Senior Fellow in Research Div.
Japanese
Functional genome analysis of immune-mediated diseases for drug discovery Mr. Hiroyuki Tsunoda Head of Discovery Technology Dept.
Japanese
Open innovation practice to realize integrated continuous biomanufacturing – Collaboration of Chugai and Cytiva Mr. Takuo Kawase Head of Bio 6 Group in API Process Development Dept.
Japanese
|
|
Oct.14(Thu.) 10 : 00 ~ 11 : 00 |
F203-204 |
| 【S-7】 Thermo Fisher Scientific (Patheon) |
|---|
|
Pre-Registration required
New Drug Modalities ( Plasmid DNA/ Viral Vector / mRNA) CDMO services updates
|
|
Mr. Koji Tanimoto Senior Director, Head of Business Development, Asia Pacific
Japanese
Building viral vector capacity and capabilities to realize the promise of gene therapies Mr. Chris Murphy Vice President and General Manager, Viral Vector Services 
Addressing technical and manufacturing challenges in mRNA platform Ms. Vincenza Pironti, PhD Global SME, Sterile Drug Products 
|
|
Oct.14(Thu.) 10 : 00 ~ 11 : 30 |
G401-402 |
| 【O-7】 |
|---|
|
Pre-Registration required
Coordinator Kohei Tsumoto 
|
|
Biotherapies as protectors of Japan Health and Economy – 5 factors to garner its power Mr. Stephane Perrey General Manager Japan
Japanese
Supply chain management as a global CDMO during the COVID-19 pandemic and our future direction Dr. Murata Hiroshi Executive Director
Japanese
Correcting imbalances among Technology, Business Development, and Regulatory Strategy & Internationalization - Toward Strengthening the Resilience of the Japanese Biopharmaceutical Industry- Dr. Fumiaki Yumoto Representative Director
Japanese
Strategy for building resilience in biotech supply chains Mr. Kozo Saiki Director, Bio-Industry Division
Japanese
the reinforcement of Bio-product supply chains Kyowa Kirin Co., Ltd
Japanese
|
|
Oct.14(Thu.) 10 : 30 ~ 11 : 30 |
F201-202 |
| 【S-8】 Kyoto University Medical Science and Business Liaison Organization |
|---|
|
Pre-Registration required
Fireside Chat: Kyoto University's Collaboration with a Foreign Pharmaceutical Company
Industry-academia collaboration is essential for universities to create innovations and implement them in society. However, in a recent internal survey at Kyoto University, a certain number of researchers answered that they were interested in industry-university collaboration but had no experience in it. The most common reason for this was anxiety for communication with companies. Coordinator Dr. Shinobu Suzuki Professor 
|
|
Dr. Shunichi Takahashi Head of Open Innovation Center Japan
Japanese
Dr. Tomoko Maeda Head
Japanese
Dr. Jun Kusunoki Director
Japanese
|
|
Oct.14(Thu.) 12 : 00 ~ 13 : 00 |
F203-204 |
| 【L-2】 LEO Pharma |
|---|
|
Pre-Registration required Simultaneous interpretation
Innovation Ecosystem driven by LEO Pharma, Venture Cafe Tokyo & CIC Tokyo
|
|
Welcome & Introduction of LEO Pharma Dr. Tord Labuda President and Representative Director 
LEO Pharma's ecosystem creation that enables future innovation Dr. Taruho Kuroda Senior Director
Japanese
Venture Café Tokyo & its social impact "creating a true innovation community" Mr. Ryusuke Komura Program Director
Japanese
Looking back the 1st year of CIC Tokyo, the largest innovation hub in Tokyo originated in Boston Dr. Masaru Nagura General Manager
Japanese
Panel Discussion Taruho Kuroda / Ryusuke Komura / Masaru Nagura
Japanese
|
|
Oct.14(Thu.) 13 : 30 ~ 14 : 30 |
F201-202 |
| 【S-10】 TAKARA BIO INC. |
|---|
|
Pre-Registration required
TAKARA BIO INC.
Coordinator Dr. Mineno Junichi Senior Corporate Officer & COO |
|
Prof. Nakai Hiroyuki School of Medicine Distinguished Professor in Molecular Medicine, Molecular and Medical Genetics, School of Medicine
Japanese
Dr. Mineno Junichi Takara Bio Inc.
Japanese
|
|
Oct.14(Thu.) 15 : 00 ~ 16 : 00 |
F203-204 |
| 【S-13】 Bayer Yakuhin, Ltd. |
|---|
|
Pre-Registration required Simultaneous interpretation
Research and Development Strategy and Open Innovation at Bayer
Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Pharmaceuticals Division at Bayer is globally conducting research and development activities with the goal of delivering innovative prescription drugs to patients, focusing on the fields of cardiovascular and nephrology, oncology, ophthalmology, gynecology, hematology, and diagnostic imaging. Coordinator Dr. Ikuo Hayashi Alliance Manager 
|
|
Bayer Pharmaceuticals’ Approach to Innovation Dr. Christian Rommel Head of Research & Development and Member of the Executive Committee of Bayer AG Pharmaceuticals 
Open Innovation at Bayer in Japan Dr. Shunichi Takahashi Head of Open Innovation Center Japan
Japanese
|
|
Oct.14(Thu.) 15 : 00 ~ 16 : 30 |
G401-402 |
| 【O-9】 |
|---|
|
Pre-Registration required
Strengthening the manufacturing base for next-generation biologics in Japan
Coordinator Prof. Kazuhisa Uchida Professor |
|
Strategy to strengthen manufacturing technology for next generation biologics in Daiichi Sankyo Dr. Masayuki Yabuta Biologics Division
Japanese
Takara Bio, the company's initiative as a CDMO for Gene Therapy Dr. Mineno Junichi Senior Corporate Officer ＆COO
Japanese
AGC’s initiatives for next generation biopharmaceutical manufacturing in Japan, US and EU Mr. Noriyuki Komuro Executive Officer, General Manager
Japanese
Proposal from Academia CPC Dr. OKAZAKI Toshihiko Associate professor
Japanese
|
|
Oct.14(Thu.) 16 : 00 ~ 17 : 00 |
F205-206 |
| 【S-14】 Okinawa Science and Technology Promotion Center |
|---|
|
Pre-Registration required
Infectious Disease Research in Okinawa: Introducing high-throughput biotechnology and its innovative products for infectious disease control
|
|
Application of "camelid VHH antibody" and "natural bacteriophage" for infectious disease control. Dr. Akikazu Murakami Chief Executive Officer
Japanese
Vaccine development for infectious diseases of animals and fishes Prof. Takeshi Arakawa CEO
Japanese
Development of antibody test kit to evaluate efficacy after COVID-19 vaccination Prof. Masaaki Ito CEO
Japanese
|
|
Oct.15(Fri.) 9 : 30 ~ 11 : 00 |
F205-206 |
| 【O-12】 Challenges revealed by COVID-19 - Tackling the next pandemic - |
|---|
|
Pre-Registration required Video Archive available after Exhibition (subject to a fee)
Challenges revealed by COVID-19 - Tackling the next pandemic -COVID-19 changed our daily lives and at the same time revealed various problems. Instead of leaving these as issues, we have to prepare for the next by recognizing them again. In this session, each expert will be on stage to talk about the issues and countermeasures for infectious diseases that have become apparent due to COVID-19. Coordinator Dr. Ohmagari Norio Director, Disease Control and Prevention Center 
|
|
Ethical, legal and social implications on COVID-19 Prof. Kaori Muto Professor
Japanese
Mr. Hidetaka Nishimura Deputy Director-General
Japanese
【Remote Presentation】 Prof. RYUICHI MORISHITA Professor
Japanese
A New Funding Scheme to Support Vaccine Research and Development in Japan Mr. Katsufumi JO Executive Director
Japanese
|
|
Oct.15(Fri.) 13 : 00 ~ 14 : 30 |
F201-202 |
| 【O-15】 What is necessary to continuously develop new modalities from Japan? |
|---|
|
Pre-Registration required
What is necessary to continuously develop new modalities from Japan?
Coordinator Mr. MASANOBU KIMURA Director, Senior Executive Officer, Head of Regulatory and Quality Assurance Headquarters 
|
|
Evolution and future possibilities of vector technology for gene and cell therapy Prof. Takashi Okada Professor
Japanese
Novel application of genome editing tool CRISPR-Cas3 in gene therapy and diagnosis Prof. Tomoji Mashimo professor
Japanese
Yukoh Nakazaki Board Director, CSO
Japanese
Prof. Takeshi Wada
Japanese
Mr. Katsuaki Ura Director
Japanese
Kouhei Tsumoto Center for Drug Discovery Research, National Institutes of Biomedical Innovation, Health and Nutrition
Japanese
|
|
Oct.15(Fri.) 13 : 00 ~ 14 : 30 |
F203-204 |
| 【O-14】 |
|---|
|
Pre-Registration required Video Archive available after Exhibition (subject to a fee)
Dx Implementation in the Pharmaceutical Industry
Coordinator Astellas Pharma Inc. 
|
|
Acceleration of innovation creation by making DX "company-wide" Ms. Satoko Shisai General Manager of Digital & IT Supervisory Div., Vice President
Japanese
Digital Transformation in Astellas to "turn innovative science into VALUE for patients" Mr. Shinya Suda Senior Vice President, Information Systems
Japanese
Next Generation Engagement for our customer Mr. Shin Tanaka Head of Data and Digital Transformation & Head of Business Excellence Department (a.i.)
Japanese
|
|
Oct.13(Wed.) 13 : 30 ~ 15 : 00 |
G401-402 |
| 【O-3】 Current status of manufacturing and expectations for supporting industries in regenerative medicine |
|---|
|
Pre-Registration required Video Archive available after Exhibition (subject to a fee)
Current status of manufacturing and expectations for supporting industries in regenerative medicine
Coordinator Dr. Tohru Hirose Forum for innovative regenerative medicine 
|
|
Reality of Manufacturing Regenerative Medical Products and the Challenges in CDMO Mr. Mori Yukio Corporate Dfficer Senior Manager, Production Engineering Department
Japanese
Commercialization of regenerative medical products Mr. Kenji Komeda Senior Director
Japanese
Challenges facing the manufacturing of clinical-grade iPSC banks. Dr. Masayoshi Tsukahara Head
Japanese
|
|
Oct.13(Wed.) 16 : 00 ~ 17 : 00 |
F201-202 |
| 【S-5】 KSP, Inc. |
|---|
|
Pre-Registration required
Activities of the RINK ～Building a network for industrialization of regenerative medicine and cell medicine that connects Kanagawa and the World～The Regenerative medicine & Cell therapy industrialization network of Kanagawa (abbreviated as RINK) was established for the purpose of creating innovation through the mutual linking and collaboration of institutions involved in the regenerative medicine and cell therapy field, in order to promote the utilization and industrialization of regenerative medicine and cell therapy. In this session, we would like to introduce the latest innovation activities in regenerative medicine and cell medicine, and discuss the role that the RINK should do in building a network for industrialization of regenerative medicine and cell medicine that connects Kanagawa and the world. Coordinator Mr. Kenichi Harada The Regenerative medicine & Cell therapy industrialization network of Kanagawa (RINK) 
|
|
Mr. Makino Yoshiyuki Kanagawa Prefectural Government
Japanese
Prof. Masaya Nakamura Professor, Keio University School of Medicine / Director, K Pharma, Inc.
Japanese
Prof. Yasunori Aizawa Associate Professor, School of Life Science and Technology, Tokyo Institute of Technology/ CEO, Logomix, Inc / Project Leader of KISTEC
Japanese
Mr. Ryuta Nomura Chairman of the board Chief Executive Officer Central Institute for Experimental Animals (CIEA) / Chairman, KING SKYFRONT Network Council
Japanese
Mr. Kiichi Kubota President and CEO, KSP, Inc.
Japanese
Mr. Yoshiya Kakizaki Director, Osaka Sanitary Co., Ltd.
Japanese
The Regenerative medicine & Cell therapy industrialization network of Kanagawa (RINK)
Japanese
Mr. Kentaro Yamaguchi Director, Kanagawa Prefectural Government
Japanese
|
|
Oct.14(Thu.) 9 : 30 ~ 11 : 00 |
F205-206 |
| 【O-5】 Challenges for industrialization of Regenerative Medicine |
|---|
|
Pre-Registration required
Challenges for industrialization of Regenerative Medicine
Coordinator Dr. Ken-ichiro Hata Representative Director, Chairman 
|
|
Pharmaceutical Company’s Perspective: Current and Future Utilization of Registry Mr. Taizo Fujita Japan Pharmaceutical Manufacturers Association, Clinical Evaluation Expert Committee (Novartis Pharma K.K.)
Japanese
Industrialization of cell therapy products from the standpoint of hospital and academia Prof. Nagamura-Inoue Tokiko Clinical Professor / Deputy Director
Japanese
Government Initiatives Toward Industrialization of Regenerative Medicine and Gene Therapy Ms. Suzuka Mohri Deputy Director
Japanese
|
|
Oct.14(Thu.) 13 : 00 ~ 14 : 00 |
F205-206 |
| 【S-12】 Minaris Regenerative Medicine Co, Ltd. |
|---|
|
Pre-Registration required
Establishing Organization and global Quality for commercial manufacturing of Regenerative Medicine
|
|
Prof. Kazuchika Furuishi Corporate Officer and General Manager, and CEO of Minaris Regenerative Medicine, LLC
Japanese
Prof. Hiroto Bando Deputy General Manager, and CEO of Minaris Regenerative Medicine Co.,Ltd.
Japanese
|
|
Oct.14(Thu.) 16 : 10 ~ 16 : 40 |
Main Stage |
| Regenerative Medicine Japan |
|---|
|
Pre-Registration not required
Efforts of university-launched venture companies, from the field of regenerative medicine
Coordinator Mr. Hiroyuki Kano The Forum for Innovative Regenerative Medicine (FIRM) 
|
|
Mr. Kenichi Nogami Co-Founder / Co-CEO
Japanese
Mr. Kengo Ueha Partner, Board Director
Japanese
|
|
Oct.15(Fri.) 10 : 00 ~ 11 : 30 |
F203-204 |
| 【O-13】 |
|---|
|
Pre-Registration required Video Archive available after Exhibition (subject to a fee)
iPS Cell Reserch and Development UpdateRegarding iPS cell research, which is being put to practical use, we will talk with the inventor, Professor Yamanaka, and President Takahashi of Vision Care, who is leading the practical use in the field of ophthalmology, and hold a panel discussion on issues and future prospects. This is a session to share with you the cutting edge of industrialization and research of iPS cells. Coordinator Prof. Miyata Mitsuru CEO 
|
|
【Remote Presentation】 Prof. Yamanaka Shinya Director/Professor
Japanese
Retinal cell therapy and immune reaction Dr. Masayo Takahashi President
Japanese
|
|
Oct.15(Fri.) 15 : 30 ~ 17 : 00 |
F205-206 |
| 【O-17】 Comparison of industry related to regenerative medicine in global |
|---|
|
Pre-Registration required
Comparison of industry related to regenerative medicine in global
Coordinator Dr. Shitaka Yoshitsugu Forum for innovative regenerative medicine 
|
|
Global ecosystem related to cell & gene therapy and current challenges in Japan Mr. Ryo Hanamura Partner
Japanese
What can Japan Learn from non-Japanese Cell/Gene Therapy Pricing Methodologies? Mr. Colin Novick Director
Japanese
Mr. Yoshihide Esaki Institute for Social Policy Issues
Japanese
|
|
Oct.13(Wed.) 11 : 30 ~ 13 : 00 |
G401-402 |
| 【O-1】 building a biotech-ecosystem, open to the world |
|---|
|
Pre-Registration required
building a biotech-ecosystem, open to the world
Japan has been a global source of innovation across many industries. In biotech, however, market growth has been staggered in the last decade, mainly due to the lack of platforms where strong start-ups are emerging and supported by risk money. Coordinator Dr. Fujimoto Toshio General Manager 
|
|
Let's go fly, Japanese biotech! Mr. Komoto Sheen Partner
Japanese
Dr. BT Slingsby Founder & Managing Partner
Japanese
Our approach to global market Mr. Hiroshi Miyake President & CEO
Japanese
Strategy for accelerating the growth of the biotech startup ecosystems Mr. Kozo Saiki Director, Bio-Industry Division
Japanese
|
|
Oct.14(Thu.) 10 : 30 ~ 11 : 30 |
| 【S-26】 The National Institute of Advanced Industrial Science and Technology (AIST) |
|---|
|
Pre-Registration required Online Seminar
Exploratory healthcare researches by AIST
Social needs related to healthcare are increasingly diversifying. To help support the medical system and improve QoL, AIST is developing new technologies that contribute to the diagnosis and treatment of diseases and the extension of healthy life expectancy on all scales from molecules to cells and to individuals. In this online seminar, we will introduce highly original studies conducted by 6 young and up-and-coming researchers in the Department of Life Science and Biotechnology. |
|
Biomaterials for fabricating designered cells Dr. Yuji TERAMURA Senior Researcher
Japanese
Simultaneous analysis of glycan and RNA in single cells Dr. Haruki Odaka Researcher
Japanese
A simple technique to measure intracellular singlet oxygen Dr. Kazutoshi Murotomi Senior Researcher
Japanese
Raman spectroscopy system for single cell analysis Dr. Yuka Akagi Researcher
Japanese
Elucidation of bile salt resistance mechanism in a thermostable probiotic lactic acid bcterium Dr. Hiroyuki KUSADA Researcher
Japanese
Development of Preventiion Methods for Alzheimer's Disease Dr. Saori Hata Senior Researcher
Japanese
|
|
Oct.14(Thu.) 12 : 00 ~ 13 : 30 |
G403-404 |
| 【O-18】 Creation and commercialization of measurements x AI platform for the science of health |
|---|
|
Pre-Registration required Video Archive available after Exhibition (subject to a fee)
Creation and commercialization of measurements x AI platform for the science of health
In the wake of the global spread of the new coronavirus disease, new sensing technologies based on digital technology have been attracting attention. With the advancement of technology, sensors and testing equipment have become smaller, lighter, and more versatile, making it easier for anyone to acquire a variety of data. Coordinator Prof. Tsuyoshi Sekitani Professor 
|
|
Development of biosensing for e-healthcare Prof. Eiichi Tamiya Director
Japanese
Mr. Makoto Tada CEO Ofice
Japanese
Exosome Biomarker Platform Mr. Ryuichi Onose Chief Executive Officer
Japanese
Electrochemical immunoassay "GLEIA" opens the way to the future of POCT Mr. HIROKAZU SUGIHARA CEO
Japanese
Maximizing the information values of brainwave data Mr. Hideki Matsubara President and Representative Director
Japanese
|
|
Oct.14(Thu.) 13 : 30 ~ 14 : 30 |
F203-204 |
| 【S-19】 Johnson & Johnson Innovation |
|---|
|
Pre-Registration required Simultaneous interpretation
【Johnson & Johnson Innovation Seminar】 Fostering Flexible Collaboration Opportunities to Support a Thriving Life Science Ecosystem
At Johnson & Johnson Innovation, we know that a great idea can come from anywhere and we are proud of our strong track record of sourcing and partnering to bring forward the most promising early-stage healthcare innovation wherever it originates. |
|
Driving Early Innovation Partnerships in Japan and Asia Pacific Dr. Jun Kusunoki Director, Country Lead- Japan
Japanese
【Fireside Chat】 Fostering Flexible Collaboration Opportunities to Support a Thriving Life Science Ecosystem Dr. Dan Wang Regional Head 
Dr. Toshio Fujimoto General Manager 
【Panel Discussion】 Exploring Opportunities and Breaking Barriers as an Early-stage Researcher Dr. Jun Kusunoki Johnson & Johnson Innovation, Asia Pacific
Japanese
Dr. Shinichi Kondo Director, Pipeline Sustainability & Partnership
Japanese
Dr. Takahisa Murata Associate Professor
Japanese
Dr. Naoyuki Masuda CEO
Japanese
Mr. Tomotsugu Ohashi Alliance Manager, Japan
Japanese
|
|
Oct.14(Thu.) 13 : 30 ~ 14 : 30 |
G401-402 |
| 【S-11】 UTokyo Innovation Platform Co., Ltd. |
|---|
|
Pre-Registration required
2021 Mid-Year Life Science Venture Overview - What’s next from the trends? -Together with the global professionals in the Japanese venture community, we will discuss the upcoming trends in the post-pandemic future. Coordinator Makoto (Mark) Ohori Partner, Chief Investment Officer, Life Science 
|
|
【Welcome & Introduction to UTokyo IPC】 Mr. Katsuhiko Oizumi President and CEO
Japanese
【Panel Discussion】 Makoto (Mark) Ohori The University of Tokyo Innovation Platform Company (UTokyo IPC)
Japanese
[Featured Review] Biotech VC Investment Trend Sakae Asanuma President & CEO
Japanese
Hiroki Ashida Senior Associate
Japanese
Takehiko Kaneko Director of the Board, Chief Medical Officer, Head of R&D
Japanese
Toru Kanke CEO
Japanese
Chika Hashimoto President
Japanese
Toshiyuki Mori CEO
Japanese
|
|
Oct.14(Thu.) 14 : 30 ~ 15 : 30 |
F205-206 |
| 【S-16】 Shonan Health Innovation Park |
|---|
|
Pre-Registration required
Cultivating a Collaborative Space for Health Innovation - Real Voices from the Life Science Ecosystem Players
In the three and a half years since its opening, Shonan Health Innovation Park, which started with 19 companies as tenants, has grown into an open innovation hub where more than 120 companies and academia have gathered. One of the characteristics of the ecosystem is the participation of a wide variety of players, including major pharmaceutical companies, drug discovery ventures, equipment manufacturers, academia, local government, and VCs, as well as the presence of more than 1,000 life science researchers. Coordinator Dr. Fujimoto Toshio General Manager 
|
|
Dr. BT Slingsby Founder, Managing Partner
Japanese
Dr. Aruto Yoshida General Manager
Japanese
Dr. Rikako Yamauchi Vice President, Head of Research Unit/Frontier Sohyaku
Japanese
Dr. Kenji Nonaka President, Representative Director and CEO
Japanese
Dr. Nobuhiko Kojima Associate Professor
Japanese
|
|
Oct.15(Fri.) 9 : 30 ~ 11 : 30 |
F201-202 |
| 【O-11】 Functional Food supports healthy and longevity society ~Important for Frailty Prevention to happy aged-life~ |
|---|
|
Pre-Registration required
Functional Food supports healthy and longevity society ～Important for Frailty Prevention to happy aged-life～
We are running into Super-aging society Japan.We convince that we need a social foundation that will realize a mature and mellow process that is both physically and mentally sound throughout our lives. Coordinator Prof. Teruo Miyazawa Professor and Project Leader 
|
|
Prof. Katsuya Iijima Profgessor
Japanese
Happy aging: mental health and frailty Dr. Masayo Kojima Department Head
Japanese
Importance of dietary habit for frailty measures: What should we focus on for the older adults? Ms. Kinoshita Kaori research fellow
Japanese
Relation between Frailty and Immune System ~ Role of Functional Foods on Gut Function ~ Prof. Kazunaga Yazawa Profgessor
Japanese
|
|
Oct.15(Fri.) 11 : 30 ~ 12 : 30 |
F205-206 |
| 【S-17】 JETRO Kyoto |
|---|
|
Pre-Registration required
Connecting with Boston's Ecosystem - The Role of BioLabs
|
|
【Seminar】The value that BioLabs brings to Japanese ecosystem Mr. Kuroda Taruho (Panelist） Japan Liaison
Japanese
Prof. Tomoyoshi Koyanagi（Moderator） Professor
Japanese
Mr. Haru Morita (Panelist） President and CEO
Japanese
Mr. Tai Harada (Panelist） Vice President
Japanese
Introduction of Life Science Startup Support Program by JETRO Ms. Kato Saki JETRO Kyoto
Japanese
|
|
Oct.15(Fri.) 15 : 00 ~ 16 : 30 |
F201-202 |
| 【O-16】 Role of exercise in healthy aging ~Unraveling the superactive senior~ |
|---|
|
Pre-Registration required
Role of exercise in healthy aging ~Unraveling the superactive senior~
Due to the outbreak of COVID-19, there has been a tendency to refrain from going out for the purpose of infection prevention. In Japan, a state of emergency was declared four times, and restraint from activities involving going out was recommended, especially in metropolitan areas. Even in the absence of emergency declarations, it is clear that physical activity among older people is declining, and this is reflected in an increase in frailty. Such self-restraint in activity leads to a drastic reduction in not only physical activity but also social interaction, resulting in a decline in physical and cognitive functions. There is a concern that the number of disabled older people will increase due to the progression of sarcopenia and frailty, as well as the deterioration of cognitive function. In this situation as well as the aging of the population, it is necessary to balance infection prevention and activity, exercise outdoors and at home, and nutritional intake that maintains an appropriate balance. To further extend healthy life expectancy, it is necessary to establish appropriate exercise habits, but it is also important to build scientific evidence. We hope that national awareness of exercise will lead to the extension of healthy life expectancy. Coordinator Dr. Hidenori Arai President 
|
|
Implication of Exercise in Healthy Longevity -View Point of Frailty Prevention- Prof. Suzuki Takao
Japanese
Development of Healthy Society through Sports Prof. Ken Nakata Professor
Japanese
Does exercise really make you healthier? Dr. Kojiro Ishii professor
Japanese
|
| 【S-25】 New Energy and Industrial Technology Development Organization |
|---|
|
Pre-Registration required Online Seminar
The contribution and potential of biotechnology for the realization of a sustainable societyNEDO believes that it is important to promote, in an integrated and organic manner, three social systems to realize a sustainable society. The three systems are a "circular economy", a "bioeconomy", and "sustainable energy". In this issue, we will introduce the research and development projects that are responsible for each social system from the perspective of biotechnology. We will also consider the contribution and potential of biotechnology in solving climate change issues and realizing a society that continues to develop in a sustainable manner. Coordinator Mr. Wataru Mizunashi Technology Strategy Center 
|
|
Outline of Moonshot Goal 4, which aims to realize sustainable resource circulation to recover the global environment, and expectations for biotechnology Hiroyuki Yamada Director
Japanese
Expectations and challenges of "Bio" in the sustainable energy field Toshiaki Kimura Project Coordinator
Japanese
Latest trends and future prospects in the bio-economy area Mr. Toshiya Imada Materials Technology and Nanotechnology Department
Japanese
|
|
Oct.13(Wed.) 13 : 30 ~ 15 : 30 |
F205-206 |
| 【S-3】 New Energy and Industrial Technology Development Organization |
|---|
|
Pre-Registration required
The contribution and potential of biotechnology for the realization of a sustainable societyNEDO believes that it is important to promote, in an integrated and organic manner, three social systems to realize a sustainable society. The three systems are a "circular economy", a "bioeconomy", and "sustainable energy". In this issue, we will introduce the research and development projects that are responsible for each social system from the perspective of biotechnology. We will also consider the contribution and potential of biotechnology in solving climate change issues and realizing a society that continues to develop in a sustainable manner. Coordinator Mr. Wataru Mizunashi Director General Bioeconomy Unit 
|
|
Outline of Moonshot Goal 4, which aims to realize sustainable resource circulation to recover the global environment, and expectations for biotechnology Dr. Hiroyuki YAMADA Director General
Japanese
Expectations and challenges of "Bio" in the sustainable energy field Dr. Toshiaki KIMURA Project Coordinator
Japanese
Latest trends and future prospects in the bio-economy area Mr. Toshiya imada Director General
Japanese
|
|
Oct.13(Wed.) 14 : 30 ~ 15 : 30 |
F201-202 |
| 【S-4】 The National Institute of Advanced Industrial Science and Technology (AIST) |
|---|
|
Pre-Registration required
Driving the Global Bioeconomy with GenomicsAIST is carrying out research and development with various approaches to realize bioeconomy society. In this seminar, we Department of Life Science and Biotechnology will introduce our recent studies using genomics approaches to advance the global bioeconomy, such as the development of an innovative technology for the derivatization of natural compounds, a new method based on network modeling to propose candidate microbial genes for the promotion of microbial engineering, and an advanced technology to introduce proteins into plant cells for genome editing. Coordinator Dr. Yasunori Chiba Director 
|
|
Innovative technology for the production of natural compounds and its derivatives (application for drug development) Dr. Kazuo Shin-ya Group Leader
Japanese
Effectiveness of Network Modeling for Microbial Breeding Dr. Sachiyo Aburatani Vice Director
Japanese
Intracellular delivery of genome editing proteins Dr. Yoshio Kato Group Leader
Japanese
|
| 【S-24】 National Institute of Technology and Evaluation |
|---|
|
Pre-Registration required Online Seminar
Value creation to the fields of healthcare and manufacturing
|
|
「The future of biotechnology driven by digital information」 Dr. Shinichiro Kato Director-General
Japanese
「Collection, analysis and integration of human intestinal environment data for utilization in the healthcare research」 Dr. Jun Kunisawa Director
Japanese
「New era of providing microbe and data ~infrastructure development by DBRP~」 Dr. Natsuko Ichikawa Director, Bio-Digital Transformation Office, Administrative Affairs Division
Japanese
「Realization of an Integrated Biofoundry by fusing Synthetic Biotechnology and Digital Technology」 Prof. Akihiko Kondo Professor
Japanese
|
|
Oct.13(Wed.) 15 : 30 ~ 17 : 00 |
G401-402 |
| 【O-4】 Data governance: its importance in digital healthcare |
|---|
|
Pre-Registration required Simultaneous interpretation Video Archive available after Exhibition (subject to a fee)
Data governance: its importance in digital healthcare
In a super-aging society it has become an important issue to improve QOL of the elderly, and to optimize social security costs. Companies utilizing big data for digital health care are required to master DATA GOVERNANCE. Coordinator Prof. Makoto Suematsu Professor 
|
|
Global data sharing: A challenge emerging in COVID-19 era Prof. Makoto Suematsu 【Remote Presentation】 Mr. Keiichi Sato Senior Director, Financial Services and Healthcare Industry
Japanese
Creating new healthcare business through utilization of personal health record Mr. Takuma Inamura Director ,Healthcare Industries Division
Japanese
【Remote Presentation】 Dr. Evren Eryurek Director of Product Management at Google 
|
|
Oct.14(Thu.) 15 : 00 ~ 16 : 30 |
G403-404 |
| 【O-10】 Business Strategy of Digital Therapeutics (DTx) |
|---|
|
Pre-Registration required Video Archive available after Exhibition (subject to a fee)
Business Strategy of Digital Therapeutics (DTx)
Coordinator Dr. Toru Kimura Representative Director, Executive Vice President, CSO 
|
|
Medical practice and medical research using digital technology Dr. Ueno Taro CEO
Japanese
Digital therapy and person centred care for dementia Dr. Nick Hird CEO and Co-founder
Japanese
Digital Therapeutics: Current status and Future Mr. Yoshinori Satomi Director
Japanese
Mr. Noriatsu Kono Chief Management Officer
Japanese
|
| 【S-23】 GenScript Japan, Inc. |
|---|
|
Pre-Registration required Online Seminar
GCT Outsourcing Success FactorsGene and cell therapy (GCT) has the potential to transform medicine by providing long-term, curative treatments for a variety of diseases. GenScript ProBio is developing a GMP platform for the delivery of viral and non-viral vectors. In this seminar, we will introduce how exactly we can make outsourcing a success. |
|
GCT Outsourcing Success Factors Mr. CHU Fredy Head of Quality 
|
|
Oct.13(Wed.) 12 : 00 ~ 13 : 30 |
G403-404 |
| 【O-2】 Opening up the new business horizon with bio-technology driven innovation collaboration of industry-government-academia to realize bio-economy |
|---|
|
Pre-Registration required
Opening up the new business horizon with bio-technology driven innovation collaboration of industry-government-academia to realize bio-economy
Coordinator Mr. Naoto Yabe Executive Director, Division General Manager, Innovation and Entrepreneurship Division 
|
|
About NEDO Bio Manufacturing Project for Realization of Carbon Recycling (tentative title) Prof. Minoru Seki Professor
Japanese
Realization of a resource-cycle society through Biotechnology ~Waste to Plastic with Bio~ Mr. Satoshi Koma Senior Manager
Japanese
Plant-Based Food,Now in the Spotlight Mr. Shigeru Ashida Soy ingredients Business Division
Japanese
CircularBio ™ Business Project -Green chemical production from new "ground resources"- Green Earth Institute Co., Ltd.
Japanese
|
|
Oct.14(Thu.) 9 : 30 ~ 11 : 30 |
G403-404 |
| 【O-6】 Toward the realization of carbon neutral in 2050 |
|---|
|
Pre-Registration required Video Archive available after Exhibition (subject to a fee)
Toward the realization of carbon neutral in 2050With the return of the United States to the Paris Agreement, the movement toward decarbonization of the world has accelerated at a stretch, and each country has launched a new strategy, seeing it as an opportunity to grow and gain international competitiveness. Japan has also declared that "Greenhouse gas emissions will be virtually zero by 2050" and the sense of crisis and momentum in the industrial world has increased. In this seminar, we will introduce the Japanese strategy of policy, management, Research and Development, as well as understanding the international situation of decarbonization. Coordinator Prof. Kuniki Kino Professor 
|
|
Mr. Nakai Tokutaro Vice-Minister of the Environment
Japanese
NEDO’s activities to carbon neutrality in 2050 Mr. Hiroaki ISHIZUKA Chairman
Japanese
Responsibilities and contributions of chemical industry to realize carbon neutrality Mr. Junpei Tsuji Associate Officer ①General Manager ②Secretary-general
Japanese
Sustainability Strategy of Ajinomoto Group – Countermeasures to climate change Ms. Chika Morishima Executive Officer, In charge of Sustainability and Communication
Japanese
|
|
Oct.14(Thu.) 15 : 00 ~ 16 : 30 |
F201-202 |
| 【O-8】 How can we make useful compounds in "decarbonization society" through renewable energy and/or carbon dioxide utilization? |
|---|
|
Pre-Registration required
How can we make useful compounds in "decarbonization society" through renewable energy and/or carbon dioxide utilization?Even in a "decarbonization society", manufacturing based on carbon skeleton should continue to be important. This indicates the need to further advance manufacturing based on renewable energy or/or carbon dioxide. Therefore, in this program, we would like to introduce the cutting edge of such research field and view the future manufacturing in a "decarbonization society". Coordinator Prof. Ishii Masaharu Professor 
|
|
Current status and prospects of biomanufacturing to realize a carbon-neutral society Prof. Masayuki Inui Group Leader, Chief Researcher
Japanese
Technologies for CO2 fixation by combination of life science and material science Dr. Souichiro Kato Senior researcher
Japanese
Sustainable bio-production from CO2 by electricity derived from renewable energy Dr. Shin-ichi Hirano Senior Research Scientist
Japanese
Development of Algae-Based Bio Jet Fuel Mr. Tomoo Mizuno Associate Director, Head of Algae^Based Biofuel Group
Japanese
|
|
Oct.13(Wed.) 14 : 00 ~ 16 : 45 |
G403-404 |
| 【A-1】 Japan Bioindustry Award, Bioindustry Research Award 2021 Ceremony and Award Lecture |
|---|
|
Pre-Registration required
Japan Bioindustry Award・Bioindustry Research Award 2021 Ceremony and Award Lecture
|
|
Japan Bioindustry Award「Pioneering Research on Systems Biology and their Industrialization for Regional Promotion」 Dr. Masaru Tomita Director General / Professor
Japanese
Japan Bioindustry Special Award「Creation, Industrialization, and Medical Applications of Biomimetic Biocompatible Polymers」 Dr. Kazuhiko Ishihara Emeritus Professor, The University of Tokyo / Specially Appointed
Japanese
Bioindustry Research Award「Unraveling the molecular network of parthenocarpy and its application for labor saving in tomato production」 Dr. Tohru Ariizumi Associate Professor
Japanese
Bioindustry Research Award「Ghost cytometry and its applications」 Dr. Sadao Ota Associate Professor
Japanese
Bioindustry Research Award「Elucidation of molecular mechanisms of plant organ regeneration and its application to the development of basic technology for clonal propagation」 Dr. Misato Ohtani Associate Professor
Japanese
Bioindustry Research Award「Research on the application and development of near infrared photoimmunotherapy」 Dr. Kazuhide Sato Designated Assistant Professor (selected-YLC program)
Japanese
Bioindustry Research Award「New neuromuscular co-culture models for disease research and drug screening」 Dr. Kazunori Shimizu Associate Professor
Japanese
Bioindustry Research Award「Development of rapid screening test for dementia using eye-tracking technology」 Dr. Shuko Takeda Associate Professor
Japanese
Bioindustry Research Award「Elucidation of molecular and cellular mechanisms underlying taste perception」 Dr. Akiyuki Taruno Professor
Japanese
Bioindustry Research Award「Innovative purification methods of proteins and cells using functional interfaces」 Dr. Kenichi Nagase Associate Professor
Japanese
Bioindustry Research Award「Studies of sustainable production and spinning mechanisms of spider silks」 Dr. Keiji Numata Professor
Japanese
Bioindustry Research Award「Grafting technology for sustainable use of plant resources」 Dr. Michitaka Notaguchi Associate Professor
Japanese
Bioindustry Research Award「Development of locus-specific chromatin immunoprecipitation technologies and their applications」 Dr. Toshitsugu Fujita Associate professor / Research Professor
Japanese
Bioindustry Research Award「Development of comprehensive single-cell genome analysis method for uncultured microbe community」 Dr. Masahito Hosokawa Associate Professor
Japanese
|
|
Oct.13(Wed.) 15 : 00 ~ 16 : 30 |
Main Stage |
| 【E-1】 |
|---|
|
Pre-Registration not required
【Main Stage A】 Promotion of Japan Bioeconomy-Strategy (1) -Three Years of the Bioeonomy-Strategy and Future Prospects
In order to realize the world's most advanced bioeconomy society in 2030, Japan bioeconomy-strategy has been positioned as a policy and is being promoted by the public and private sectors with the Cabinet Office as the commander-in-chief. In this session, we will review the progress made so far from 2019 and discuss the future direction of the strategy. Coordinator Dr. Hitoshi Kuboniwa Japan Bioindustry Association 
|
|
Grand design including data strategy in the healthcare field to enhance drug discovery Mr. Yoshizawa Nao GRiT Partners Law office
Japanese
【Remote Presentation】 Junichi Koga Senior Advisor
Japanese
Executive Director, Division General Manager, Innovation and Entrepreneurship Division
Japanese
Japan’s Bioeconomy Strategy’s Featuring Points Mr. Deputy Director General
Japanese
|
|
Oct.14(Thu.) 10 : 30 ~ 12 : 30 |
Main Stage |
| 【E-2】 Create Bio-communities in Japan |
|---|
|
Pre-Registration not required
【Main Stage A】Create Bio-communities in Japan
Speedy R&D to market introduction with investment by gathering large companies, startups and investors under one roof. Coordinator Mr. Takafumi Kakudo Deputy Director General 
|
|
Cabinet Office
Japanese
Hokkaido Prime Bio-community Prof. Kiyohiro Houkin President
Japanese
Tsuruoka Science Park makes Japan exciting Prof. Masaru Tomita Director General
Japanese
Nagaoka Bio Community～Aiming for a bio-community with complete recycle of local resources Mr. Tatsunobu Isoda Mayor of Nagaoka
Japanese
Characteristics and future image of Fukuoka bio-community Mr. Okubo Tsutomu Mayor
Japanese
Towards Formation of the Greater Tokyo Biocommunity Mr. Nagayama Osamu Greater Tokyo Biocommunity Council, Chairman (Chugai Pharmaceutical Co., Ltd. Honorary Chairman)
Japanese
Formation and Efforts of Bio-community Kansai (BiocK) Dr. SAKATA TSUNEAKI Deputy Chairman
Japanese
|
|
Oct.15(Fri.) 15 : 00 ~ 17 : 00 |
F203-204 |
| 【S-15】 Japan Agency for Medical Research and Development |
|---|
|
Pre-Registration required
The Human Frontier Science Program and the transformative power of basic scientific research to change society
|
|
From human frontier science towards health care as a global sustainability industry Prof. Pavel KABAT Secretary General 
The Aim of AMED and the Significance of HFSP - The Essence of Interdisciplinary Fusion and International Collaboration Dr. Yoshinao MISHIMA International Human Frontier Science Program Organization Trustee
Japanese
Fun to Basic Science Prof. Shigekazu NAGATA International Human Frontier Science Program Organization President
Japanese
Cutting edge interdisciplinary research for a challenge at the frontier of nano-bioscience Prof. Keiichi NAMBA Specially Appointed Professor
Japanese
Next-generation RNA technology accelerated by international research Prof. Hirohide SAITO Deputy Director, Professor
Japanese
Turn innovative science into VALUE for patients Dr. Taro MASUNAGA Executive Vice President
Japanese
New Drug Creation and Basic Research Dr. Hitoshi KUBONIWA Japan Bioindustry Association Chairman of the Steering Committee
Japanese
|
